- Current report filing (8-K)
02 April 2012 - 10:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): April 2, 2012
AVI BioPharma, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Oregon
|
|
001-14895
|
|
93-0797222
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
3450 Monte Villa Parkway, Suite 101
Bothell, WA 98021
(Address of principal executive offices, including zip code)
(425)
354-5038
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On
April 2, 2012, AVI BioPharma, Inc. issued a press release announcing top-line results from its Phase IIb study evaluating eteplirsen for the treatment of Duchenne muscular dystrophy. A copy of the press release is attached hereto as Exhibit
99.1 and is incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press release dated April 2, 2012.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
AVI BioPharma, Inc.
|
|
|
By:
|
|
/s/ Christopher Garabedian
|
|
|
Christopher Garabedian
|
|
|
President and Chief Executive Officer
|
Date: April 2, 2012
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press release dated April 2, 2012.
|
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Sarepta Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
More News Articles